Targeting the tumour vasculature: from vessel destruction to promotion
S Guelfi, K Hodivala-Dilke, G Bergers - Nature Reviews Cancer, 2024 - nature.com
As angiogenesis was recognized as a core hallmark of cancer growth and survival, several
strategies have been implemented to target the tumour vasculature. Yet to date, attempts …
strategies have been implemented to target the tumour vasculature. Yet to date, attempts …
An update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma
M Rosellini, E Tassinari, A Marchetti… - Expert Opinion on …, 2023 - Taylor & Francis
Introduction Significant advances have been made in the first-line therapy of metastatic renal
cell carcinoma (mRCC) since the approval of immune-based combinations, including …
cell carcinoma (mRCC) since the approval of immune-based combinations, including …
Ferroptosis-associated genes and compounds in renal cell carcinoma
C He, Q Li, W Wu, K Liu, X Li, H Zheng… - Frontiers in …, 2024 - frontiersin.org
As the main type of renal cell carcinoma (RCC), clear cell RCC (ccRCC) is often associated
with the deletion or mutation of the von Hippel Lindau (VHL) gene, enhancement of glucose …
with the deletion or mutation of the von Hippel Lindau (VHL) gene, enhancement of glucose …
15 years of patient-reported outcomes in clinical trials leading to GU cancer drug approvals: a systematic review on the quality of data reporting and analysis
M Paravathaneni, H Safa, V Joshi, MK Tamil… - …, 2024 - thelancet.com
Background Standardized, high-quality PRO data reporting is crucial for patient centered
care in the field of oncology, especially in clinical trials that establish standard of care. This …
care in the field of oncology, especially in clinical trials that establish standard of care. This …
Immune checkpoint inhibitor combination therapy leads to more nephrotoxicity in advanced renal cell carcinoma patients
Y Song, S Han, T Xu - World Journal of Urology, 2023 - Springer
We were interested to read the impressive study by Tan et al. in World Journal of Urology [1]
and would like to congratulate the authors for their interesting findings. Tan et al …
and would like to congratulate the authors for their interesting findings. Tan et al …
Downregulation of RNA binding protein 47 predicts low survival in patients and promotes the development of renal cell malignancies through RNA stability …
C Wang, W Li, X Meng, H Yuan, T Yu, W Yang… - Molecular …, 2023 - Springer
RNA binding proteins (RBPs) are crucial for cell function, tissue growth, and disease
development in disease or normal physiological processes. RNA binding motif protein 47 …
development in disease or normal physiological processes. RNA binding motif protein 47 …
BAP1 loss confers sensitivity to bromodomain and extra-terminal inhibitors in renal cell carcinoma
W Shi, X Liu, R Zhou, G Zhang, L Chen, Y Zhou… - Anti-Cancer …, 2024 - journals.lww.com
The tumor suppressor gene BRCA1 associated protein-1 (BAP1) is frequently mutated in
renal cell carcinoma (RCC). BAP1 loss-of-function mutations are associated with poor …
renal cell carcinoma (RCC). BAP1 loss-of-function mutations are associated with poor …
An epistolary account of cabozantinib's significance in the combat against renal cell, hepatocellular, and thyroid carcinoma from the perspective of a cancer combatant
S Bhattacharya - Cancer Research, Statistics, and Treatment, 2023 - journals.lww.com
Letters to Editor anti‑angiogenic multi‑receptor tyrosine kinase inhibitors in osteosarcoma
and Ewing sarcoma. Front Oncol 2023; 13: 1013359. 12. Patell K, Kurian M, Garcia JA …
and Ewing sarcoma. Front Oncol 2023; 13: 1013359. 12. Patell K, Kurian M, Garcia JA …